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                                    ABSTRACT 
Dendritic cells (DCs) are prime mediators of innate and adaptive immunity. In humans 
the DC population comprise only 0.1% of all leukocytes, making their isolation and ex 
vivo manipulation difficult. Since study of  DC activity in vitro requires large numbers of 
DCs to be readily available, a cell line model, KG-1, was selected. KG-1 cells are a 
cytokine-responsive human CD34+ myelomonocytic cell line and can be induced to 
differentiate to a DC phenotype. A range of differentiation agents and protocols were 
compared, and differentiation efficiency was determined using both morphological 
features and cell surface marker expression. Expression of CD83, CD11c, CD123, CD86, 
HLA-DR and DC-SIGN was assessed by immunofluorescence and flow cytometry. KG-1 
cells stimulated with 10 ng/ml PMA and 100 ng/ml Ionomycin were found to be the ideal 
model for obtaining Dendritic Like Cells (DLCs) in vitro. The effect of lactic acid 
bacteria on KG-1 differentiation was also tested using two immunomodulatory strains, 
Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052. After 5 days of 
incubation with R0011 the KG-1 cells expressed DC-specific surface markers CD83, 
CD86, CD11c, CD123, DC-SIGN and HLA-DR. Lactobacillus rhamnosus R0011 
induced a marked rise in CD83 expression with a mean fluorescence intensity of 115.3 
after 5 days, suggesting this strain promoted KG-1 differentiation to DLC. Analysis of 
cytokine by KG-1 DLC indicated that constitutive production of pro-inflammatory 
cytokines TNF-α and IL-12 was minimal. However IL-10 and TGF-β were detected after 
TLR-agonist stimulation of R0011-differentiated KG-1s. This study aimed to develop 
and assess the KG-1 cell model for screening effects of mediators and microbes on DC. 
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                                  INTRODUCTION 
The immune response 
 
               The Immune system is comprised of various organs, cells and proteins and other 
mediators that aid the host to fend off infections. Immune responses are mediated through 
immune cells that can recognize the invading microorganisms and initiate secretion of 
chemokines and cytokines that further aid in eliminating infectious agents. Infectious 
agents may be viruses, bacteria, fungi, protozoa or parasitic worms.  
 
               The immune response is classified into two types, either innate or adaptive 
immune responses. The innate immune response is an ancient host immune defence 
mechanism which is immediate and nonspecific. Innate immunity provides front line 
defence against pathogens that can cause disease and tissue damage. The innate immune 
system distinguishes to some extent between self and non-self and responds to both 
pathogenic and non-pathogenic microorganisms. It also triggers and optimizes the 
adaptive immune response (Janeway, 2005; Pier, 2004). The innate immune defence 
system utilizes varied mechanisms which work towards preventing infections. Non-
specific components include epithelial surfaces of the body which act as barriers to 
invasion by microorganisms, antimicrobial peptides, secreted proteins (cytokines, 
chemokines, plasma proteins and proteins of complement system) and circulating and 
localized phagocytic cells (macrophages, dendritic cells and neutrophils). Infectious 
disease often occurs when microorganisms can evade or overwhelm the innate immune 
response to establish a local infection and then replicate further to allow dissemination in 
the body. Inflammatory responses are elicited when pathogens spread and are countered 
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by recruiting effector cells and molecules of the innate immune system from local blood 
vessels. The rapidly induced innate mechanisms can occur over several days during 
which adaptive immune system prepares itself to mediate highly specific responses 
towards pathogens delivered to local lymphoid tissue by Dendritic cells (DCs). The 
adaptive immune system mechanism clears infectious agents by targeting structures 
specific to pathogens and has the unique property of developing immunological memory 
(Janeway, 2005). Innate immunity is rapid, recognizes a broad class of pathogens and can 
interact with a range of molecular structures. The cells of the innate immune system 
possess receptors known as pathogen recognition receptors (PRRs) and recognize 
pathogen-associated molecular patterns (PAMPs) present on microorganisms. Adaptive 
immunity on the other hand is not inherited in the genome of the organism and requires 
time for its onset. Key cells of the adaptive immune system are T and B cells which use 
highly specific receptors. These receptors are encoded in multiple gene segments and 
undergo a process of gene rearrangement early in B and T cell maturation. The final T-
cell receptor (TCR) and B-cell receptor (BCR) are generated through the gene 
rearrangement process producing lymphocytes with unique and highly specific antigen 
receptors. Contact of a lymphocyte and TCR or BCR with appropriate antigen leads to 
lymphocyte activation, provided the appropriate co-stimulatory signals are present. T 
cells recognize antigens presented by class I and class II MHC molecules, carried on 
professional APC, which include macrophages and DCs. This mechanism allows 





Toll-like receptors (TLRs): History and functions.  
               TLRs were first studied in Drosophila in 1988 during embryogenic polarity 
gene screening (Fernando, 1999). It was also seen that tobacco plants develop resistance 
against Tobacco Mosaic virus due to the N gene product. The N protein bears homology 
to the Drosophila toll and mammalian IL-1 receptor intracellular domains. This 
phenomenon was also observed in the Arabidopsis RPP5 protein, which protects against 
the downy mildew pathogen (Meng, 1999). The activation of immune genes in 
Drosophila is dependent upon Drosophila Dif and Relish, which are the homologues of 
mammalian NF-κB. In Drosophila the Toll receptors bind to the adaptor tube which is a 
homolog of mammalian MyD88, a key intermediate in TLR-mediated intracellular 
signalling. The adaptor tube binds to kinase Pelle, a homologue of IRAK (Interleukin-1 
receptor associated kinase) which further leads to transcription of genes that mediate the 
antimicrobial pathways. 
 
Mechanism of TLR signalling during immune response.  
              The binding of microbial ligands to their specific TLRs results in 
homodimerization of the TLRs and recruits MyD88 and MAL to the receptor complex. 
This in turn recruits IRAK which then binds to Tollip (Toll interacting protein) in the 
cytoplasm. IRAK activates NF-κB-inducing kinase (NIK) or transforming growth factor-
β-activated kinase (TAK-1) through the assistance of co-factor protein TRAF6 (Tumour 
necrosis factor receptor-associated factor 6). NIK or TAK-1 later phosphorylate IKK 
(Inhibitor of κB kinase) which in turn phosphorylates the protein inhibitor IκB. 
Phosphorylation ultimately leads to the degradation of IκB, leading to the release of 
transcription factor NF-κB which then translocates to the nucleus and causes gene 
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transcription leading to the production of cytokines (Pier, 2004; Takeda and Akeda, 
2004). (Please see the Appendix for a diagram illustrating this pathway). 
 
Types of TLRs 
               The TLRs constitute 11 different functional receptors that identify molecular 
patterns present in bacteria, fungi, viruses and parasites (Della-Bella et al., 2008). The 
TLRs bind to PAMPs on the microorganism thus facilitating their recognition by the DC. 
The various TLRs include TLR2 which recognizes Gram positive and mycobacterial 
PAMPs as well as bacterial lipopeptide, lipoteichoic acid and peptidoglycan. TLR3 is 
required for the recognition of double stranded viral RNA, TLR4 for lipopolysaccharide, 
a chief component of Gram negative outer membranes, and TLR5 recognizes flagellin, a 
subunit of flagella. TLR7 recognizes imiquimod and single stranded RNA which is a 
feature of viral infection and TLR9 recognizes bacterial DNA or unmethylated CpG 
DNA sequence of prokaryotes. Some TLR’s work in combination. For example TLR1 
together with TLR2 recognizes triacylated bacterial lipopeptide (Furrie et al., 2004). 
Another combination involves TLR2 together with TLR6 and TLR1 recognizing 
peptidoglycan, yeast cell wall zymosan and phenol soluble modulin (Ida et al., 2006; 
Pier, 2004; Lore et al., 2003).    
 
Organs and cells of the immune system                
               The immune system is comprised of primary lymphoid organs (generative or 
central lymphoid organs) and secondary lymphoid organs (or peripheral lymphoid 
organs). The primary lymphoid organs are bone marrow and thymus, and the secondary 
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lymphoid organs are the spleen, lymph nodes, and mucosa associated lymphoid tissue 
(MALT). MALT includes GALT: the mucosal barrier composed of the epithelial lining 
of the gastrointestinal tract as well as organized lymphoid tissue of the gastrointestinal 
tract such as Peyer’s patches (PPs) and dispersed lymphoid cells within the epithelium 
and lamina propria ( Piers, 2004). Cells involved in immune mechanisms are from 
precursors in the bone marrow. During hematopoesis, bone marrow derived stem cells 
differentiate into either mature immune cells or precursor cells which further differentiate 
into mature cells in other organs of the body. Stem cells give rise to both lymphoid and 
myeloid progenitor cells. The lymphoid stem cells give rise to T-cells, B-cells and natural 
killer cells. The myeloid stem cells give rise to neutrophils, eosinophils, basophils, mast 
cells and also monocytes. Monocytes further give rise to dendritic cells and macrophages 
(Janeway,  2005). 
 
Dendritic cells  
              Dendritic cells (DC) are now known to be the major antigen presenting cells 
(APC) of the immune system. DC arises from DC precursors from hematopoietic 
progenitor cells (HPC) in the bone marrow (Paul, 2003; Stephens et al, 2008; St Louis et 
al., 1999). The DC precursors are monocytes and plasmacytoid cells which are also 
known as pre-DC and pre-DC2 respectively (Paul, 2003). DCs are present in blood and 
secondary lymphoid organ and are also found localized in skin (Langerhan cells), lungs, 
intestine and GALT (Gut associated lymphoid tissue). They were identified for the first 
time in peripheral lymphoid organs of mice by Steinmen and colleagues in 1972 
(Steinman and Cohn, 1973). DCs belong to the innate immune system and act as front 
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line sentinels of host defence against microbial invasion. They initiate and control the 
adaptive immune response by stimulating T and B cells of the immune system and 
presenting antigens to T cells (Ida et al., 2006). T cell receptors (TCRs) recognize 
antigens presented by Major Histocompatibility Complex (MHC) proteins on DCs. 
Presentation of antigens by class I MHC stimulates cytotoxic T lymphocyte (CTL) 
activity, which causes the destruction of virus infected cells. Presentation of antigen by 
MHC class II molecule stimulates helper T cell (Th) activity which results in immune 
regulatory and activating effects (Satthaporn and Eremin, 2001).  
                
               DC may be classified as either immature DC (iDC) or mature DC. iDCs are               
found scattered in nonlymphoid organs throughout the body and are unable to stimulate              
T cells.  iDCs can take up the antigens at the peripheral sites and then migrate to the T               
cell areas of the secondary lymphoid organs where they undergo maturation, process               
the phagocytised antigen and present it using MHC class I and MHC class II proteins               






cytotoxic T cells (Satthaporn and               
Eremin, 2001; Sallusto and Lanzavecchia, 1994).  
 
A novel cell line model used to generate DCs in vitro 
              DCs are found as a minute population in blood and this makes large scale studies 
laborious as they are difficult to isolate from peripheral blood. Study of DC from              
other locations in humans such as the GALT, can be even more challenging due to             
difficulty in obtaining appropriate tissue. Adding a further difficulty to this, DCs can             
be easily damaged in the isolation process. Therefore a new cell line model using KG-1             
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cells would be useful to circumvent this problem. KG-1 cells are a cytokine-responsive               
human CD34
+
 myelomonocytic cell line derived from bone marrow aspirate of a               
patient with erythroleukemia which later evolved into acute myelogenous leukemia               
(Koeffler, H.P and Goldie, D.W, 1978; St.Louis et al., 1999). On stimulation with               
certain agents KG-1 cells have been reported to differentiate into DLCs (Dendritic like              
cells) which are characterized by production of “dendrites” or “neurites” and also by               
expression of DC specific markers on their cell surface (St Louis et al., 1999; Teobald et              
al., 2008; Berges et al., 2005; Hulette et al., 2001; Bharadwaj et al., 2005). 
 
Dendritic cell surface markers and DC lineage 
               Cluster of differentiation or CD numbers are used to designate the presence of 
specific molecules on the surface of cells within the immune system. These cell surface 
markers are often identified by specific antibodies and help to identify the cell types, their 
differentiation stage and even the activity of the cell. The study of the cell surface 
markers present on DCs provides a basis for comparison with the markers that are 
produced on differentiated KG-1s. The major cell surface markers found on DCs are 
CD83, CD11c, CD123, CD86, HLA-DR, DC-SIGN (Dendritic cell Specific Intercellular 
adhesion molecule 3 (ICAM-3)-Grabbing Non integrin and CD80 (St. Louis et al.,1999; 
Della Bella et al., 2008).             
 
               Although the precise function of CD83 is unknown it is thought to be a mature 
DC specific marker that plays a role in antigen presentation and or lymphocyte activation. 
Structurally it is a membrane of the immunoglobulin super family and is made up of a 
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single chain transmembrane glycoprotein (43KD) (St. Louis et al., 1999; Della Bella et 
al., 2008; Lechmann. et al., 2001). CD11c is found on myeloid DCs (mDCs) as well as 
Natural Killer cells (NK cells), B and T cell subsets and is involved in adhesion and  
cytotoxic T lymphocyte (CTL) associated killing. It is a 145-150KD type I 
transmembrane glycoprotein. The ligands for CD11c are CD54, fibrinogen, iC3b,               
ICAM-1 and ICAM-4 (St.Louis et al., 1999; Kurts et al., 2008).   
 
               CD123 is a plasmacytoid DC (pDC)-specific marker and is the Interleukin-3               
receptor. The protein IL-3 receptor is a dimer made up of an α sub unit and a signal-              
transducing β subunit which together bind to IL-3 with high affinity. Structurally              
CD123 is made up of only the 70 KD transmembrane α chain of the IL-3 receptor               
(St. Louis et al., 1999; Ida et al., 2005; Della Bella et al., 2008). CD209, also known as              
DC-SIGN, are molecules expressed on the surface of mDCs. CD209 binds to ICAM-3,               
ICAM-2 and Butyrophilin (BTN2A1) and mediates dendritic cell migration and T cell               
proliferation. CD209 is a receptor for HIV-1, West Nile virus, hepatitis C, and certain               
bacteria and parasites. It plays a role in capture and internalization of these pathogens.               
CD209 is a 44 KD type II transmembrane glycoprotein and a member of the C-type               
lectin family (St. Louis et al., 1999; van Kooyk, 2003). 
 
               HLA-DR (MHC class II) is a marker of professional APCs and its expression              
increases with DC activation. HLA-DR is required for peptide presentation to CD4
+
 T             
cells. It is a heterodimeric cell surface glycoprotein made up of 36KD α (heavy chain)             
and a 27KD β (light) chain (St. Louis et al., 1999). CD80 (B7-I) and CD86 (B7-2) are              
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co-stimulatory molecules expressed by APCs. They play a critical role in T-cell             
activation by binding to CD28 on the T cell surface. CD86 is involved in             
immunoglobulin class switching and triggering NK cell mediated cytotoxicity (St. Louis             
et al., 1999; Ackerman and Cresswell, 2003). 
 
The DC lineage 
               Dendritic cells and monocytes are derived from a common precursor cell 
referred to as the macrophage and dendritic cell precursor or MDP (Laffont and Powrie, 
2009). MDPs differentiate into common DC precursors (CDPs), which further 
differentiate into DC subsets. DCs can also be derived from monocytes under 
inflammatory conditions and in certain tissue locations, such as intestinal tissues. Human 
blood DCs can be grouped into either mDC or pDC types. The mDC are HLA-DR+ 




 (Ida et al., 2006; Masten et al., 2006). They are 
found as immature cells in skin and mucus membranes. On exposure to a “danger signal” 
such as an invading pathogen, they mature and migrate to the local draining lymph node. 
Within the lymph node they process and present antigen to T cells and express co-
stimulatory molecules CD80 and CD86 to activate T cells specific for the antigen 
presented. mDCs produce the cytokines IL-12 and TNF-α (Ida  et al., 2006). pDC are 







. They produce IFN-α and TNF-α in large amounts (Ida et al., 
2006), and also produce a variety of chemokines. mDCs and pDCs differ in their  
response to TLR agonists. mDC respond to theTLR4 agonist Lipopolysaccharide (LPS) 
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and TLR3 agonist Poly (I:C) while pDCs respond to the TLR7 agonist imiquimod and the 
TLR9 agonist CpG oligonucleotide (Della-Bella et al., 2008). 
 
Table 1: Cell Surface markers present on mDCs and pDCs. 
DC lineage  Cell surface 
markers 






class II) CD11c high, 
CD 123 low  
IL-12 and TNF-α  LPS (TLR4) and poly 





low and CD123 high  




Roles of DC Cytokines          
               DCs produce cytokines upon stimulation with TLR-agonists and other stimuli. 
The chief cytokines produced are IL-12, TNF-α, IL-10, TGF-β and IFN-α. Determination 
of the cytokine profile produced by DC helps in determining the DC subset or lineage. 
 
               IL-12 is a proinflammatory cytokine that plays a role in both innate and 
adaptive immunity (Watford et al., 2003). It is naturally produced by epithelial cells,               
dendritic cells, macrophages and B cells during infection. IL-12 is a multimer linked by               
disulphide bonds, forming a p70 heterodimer which consists of p35 and p40 subunits. 
p40 is a dominant effector molecule produced by epithelial cells. IL-12 binds to IL-12 
receptors found on T cells and NK cells. IL-12 plays a critical role in the Th1 response 
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leading to Th1 cell differentiation from Th0 cells and promotion of Th1-associated 
activities, including macrophage activation (Paul, 2003; Ashman et al., 2011). 
 
               TNF-α was identified in 1975 and has an important role in immune system              
development, inflammation and apoptosis. It is produced by DC, mast cells, monocytes, 
macrophages, T and B lymphocytes, NK cells, neutrophils, endothelial cells, smooth and 
cardiac muscle cells, fibroblasts and osteoclasts (Bradley, 2008). TNF-α is also involved 
in cell differentiation and cell proliferation. TNF-α triggers signal transduction by 
binding to receptors TNFR1 and TNFR2, resulting in active NF-κB entering the nucleus 
of the cell, initiating transcription of several genes associated with inflammation 
(Bradley, 2008; Paul, 2003). DCs and T cells express TNF family members RANK 
(Receptor Activator of Nuclear Factor-κB) and RANKL (ReceptorActivator of Nuclear 
factor-кB Ligand) respectively. RANK is a receptor of RANKL.DCs, after antigen 
presentation to and activation of naive T cells, are eliminated by apoptosis through TNF 
family molecules TRAIL(Tumour necrosis factor-related apoptosis- inducing ligand), 
FasL and TNF-α produced by activated T cells. This is done to prevent excessive T cell 
activation by mature DCs. Failure of DC elimination is observed in patients with 
autoimmune lymphoproliferativesyndrome (ALPS) which is an inherited autoimmune 
disease of lymphocyte homeostasis (Leibbrandt, 2010). 
 
               IFN-α is involved in innate immunity and is chiefly produced by pDC during                
viral infections. IFN-α is synthesised when intracellular MyD88 is activated following                
ligand binding to TLR 7, 8 or 9. Activated MyD88 in turn induces antiviral responses               
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by forming a complex with transcription factor IRF7. The death domain of MyD88               
interacts with the inhibitor domain of IRF7, resulting in the activation of IFN-α               
dependent promoters. IRF7 also binds TRAF6 leading to INF-α synthesis (Sato et al.,                
2004). IFN-α is then released to induce protective anti-viral defences in neighbouring               
cells, such as induction of RNA activated protein kinase. As IFN-α is produced only by               
pDCs and not mDCs, its identification either in the culture supernatant or within the               
cell helps in classifying the in vitro derived DLCs as belonging to the pDC lineage. 
 
               IL-10 is an 18.4KDa regulatory cytokine that down regulates the synthesis of 
pro-inflammatory cytokines including IL-2, IL-3, TNF-α, IFN-γ and GM-CSF. It is 






Treg cells in the gut mucosa, B cells, monocytes 
and keratinocytes  (Siddiqui and Powrie, 2008; Zeuthen et al., 2006). IL-10 plays a major 
role in inhibiting Th1 function and favours Th2 development (Paul, 2003).  
 
               TGF-β is a key regulatory molecule having effects on a variety of cells which              
include monocytes, Treg cells, B cells, NK cells, macrophages, epithelial cells. It is an              
anti-inflammatory cytokine endogenously secreted by GALT DCs which drive Treg cell 
differentiation from naive T cells in the GALT (Siddiqui and Powrie, 2008). TGF-β is 
also involved in B cell class switching to IgA. TGF-β has three isoforms: TGF-β1, TGF-
β2 and TGF-β3 with TGF-β1 being the most prominent among them. TGF-β is secreted 
in latent form and needs to be liberated from the latency associated protein, LAP and 




Other DC subsets 
               Although conventionally DCs were classified based on their origin as either 
being myeloid or lymphoid, DCs are also classified based on the tissue where they reside 
steadily. Using location as reference point, DCs have been classified as either interstitial 
or tissue-derived DC and blood or lymphoid-derived DC (Adorini et al., 2009). The 
tissue-derived DCs are skin DC, thymus DC, lung DC, hepatic DC, spleen DC, Peyer’s 
patches DC (PP DCs), Mesenteric Lymph node DC (MLN DCs) and DCs of the intestinal 




 DC, which 
arise from pre-dendritic cells found in bone marrow and require growth factor flt3 for 




 DC which depend on 
growth factor M-CSF (macrophage colony stimulating factor) for their development 
(Laffont and Powrie, 2009). In addition there are many more DC subsets that have been 
identified. For example cDC are postulated to originate directly from lymphoid 
progenitors or upon viral induced activation of immature pDC. This cDC subtype was 
found to be similar to the conventional DC originally identified by Steinman and Cohn. 









 in tissues) (Reizis, 2011). 
 
               Another subtype of DC identified were tolerogenic DC (tDC) which originate 
from immature DC (iDC). tDc can be either derived naturally from hematopoietic 
precursors or may be induced from other DCs having received instructive signals that 
lead them towards their tolerogenic phenotype. tDCs are induced during disease which 
may be due to pathogens or due to tumour formation. Additionally it was also seen that 
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Treg cells induced tDC by a mechanism termed as “infectious tolerance”. tDC can be 
produced by experimental manipulation using biomolecules like TGF-β, Hepatocyte 
Growth Factor (HGF) and vitamin D3 metabolites, by using immunosuppressive drugs 
prednisolone or dexamethasone or by genetic manipulation (Maldonado and von 
Andrian, 2010). 
 
GALT and the Dendritic cell 
          The intestinal tract of mammals is constantly exposed to the external environment 
and can therefore be easily colonized and invaded by viruses, bacteria, fungi and 
parasites. Immature DCs are localized in the mucosa of the small intestinal tract where 
they reside in the PPs, lamina propria and the draining MLNs making up the GALT 
(Smith and Nagler-Anderson, 2005). PPs are overlaid with special cells known as M 
(microfold) cells that can sample antigens and microorganisms in the gut lumen. These M 
cells deliver antigen by transcytosis to the subepithelial dome that contains antigen 




DC, which are 




 DC, which develop from monocytes in response to M-CSF (Laffont and 
Powrie, 2009). CX3CR1 is a chemokine receptor, and CX3CR1
+
DCs in the lamina 
propria of the small intestine extend their dendrites between epithelial tight junctions to 
directly sample the luminal contents (Artis, 2008; Mohaamadzadeh et al., 2008) 
facilitating their role as APCs that act as principle stimulators of naive T-helper cells, and 





 DC are thought to regulate the generation of Treg cells and 
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immunoglobulin A (IgA)-producing B cells through the production of the cytokines 
TGF-β and IL-10 which strongly contribute to immune homeostasis (Zeuthen et al., 
2005; Laffront and Powrie, 2009). IgA production by the immune cells in the gut is a 
result of microbial colonization in the intestine. The human intestine can secrete 3 grams 
of secretory IgA (SIgA) in the intestinal lumen each day. The major sites for IgA 
generation are the PPs which develop during embryogenesis and the isolated lymphoid 
follicles (ILFs) that develop following bacterial colonization early after birth (Suzuki and 
Fagarasan, 2008). SIgA acts as a barrier for the invasion of both intestinal microbiota and 
pathogens. PPs are the major sites for IgA production and contain germinal centers (GC) 
which are special microenvironments allowing interactions between the B cells, DC and 
follicular T helper cells. Interaction between these cells activates B cell proliferation and 
expression of activation-induced cytidine deaminase (AID) which is a critical molecule 














. PP DCs are important in controlling the mucosa-tropism of lymphocytes 
by induction of homing molecules α4β7 integrin and CCR9, a chemokine receptor, on 
antigen primed B and T lymphocytes, through production of retinoic acid from vitamin A 
(Takahashi et al., 2009).                  
                
               Studies have shown that IgA CSR is regulated by inducible nitric oxide 
synthase (iNOS) which is expressed by PP DCs. iNOS production is induced in PP DCs 
by TLRs recognizing commensal bacteria. iNOS controls T-cell dependent IgA CSR by 
TGF-β whereas T-cell- independent IgA CSR is regulated by APRIL (A Proliferating 
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Inducing Ligand ) and BAFF (B-cell-Activating Factor), which can be produced by DCs               
as well as by IECs (Mohamadzadeh et al, 2008). In summary, intestinal DCs are now 
believed to play  key roles not only in antigen presentation to T cells, but also in directing 
development of regulatory T cells (Treg) and  in supporting IgA class switching in the 
MALT.  
  
Role of DCs in intestinal homeostasis 
               PP DCs produce large amounts of IL-10, an immunomodulatory cytokine that 
plays a role in preventing autoimmunity. Lamina propria DCs take up antigen (which 
may include commensal bacteria and apoptotic intestinal epithelial cells in addition to 
antigen from infectious agents) to Mesenteric lymph nodes (MLNs). DCs that have 
migrated to MLNs or those located in the PPs interact with B and T cells and initiate anti-
inflammatory activity in the intestine due to IL-10 production. Intestinal DCs promote the 
development of forkhead box P3 (FOXP3)
+
 regulatory T cells (Treg cells) from naive T 
cells thereby diverting T cells that may strongly react to the antigen to a T cell that is 
tolerogenic in its nature. The induction of FOXP3 expression by naive T cells is mediated 
by TGF-β produced by intestinal DCs. FOXP3 production is also dependent upon retinoic 
acid synthesis by DC. It has been noted that IL-10, TGF-β and retinoic acid are involved 
in preventing autoimmune diseases (Coombes and Powrie, 2008).      
 
Gastrointestinal microbiota, and their interaction with immune system  
               The mammalian intestine is a home to a vast and diverse commensal microbiota 
which in return promote angiogenesis, development of intestinal epithelium and 
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protection against tissue injury. They also aid in digestion, absorption and storage of 
nutrients, especially the plant-derived nutrients that would be otherwise inaccessible to 
the host. In addition the gut microbiota prevents colonization by pathogens by competing 
with them for nutrients and an environmental niche in the intestine. They also secrete 
antimicrobial peptides that protect the host against pathogens. “Dysbiosis” is defined as a 
change in the composition of the commensal microbiota in the intestine which may lead 
to Irritable Bowel Syndrome (IBD) and necrotizing enterocolitis (Artis, 2008). It is 
known that the immune cells of the gut are influenced by the stimuli coming from the 
commensal microbiota. Intestinal homeostasis is a mechanism by which the immune 
system discriminates between pathogens and the intestinal microbiota. Pathogens in the 
intestinal mucosa elicit an immune response, while the commensal microbiota tends to 
promote IgA production and regulatory activity. Any imbalance in this mucosal immune 
system may lead to problems such as food allergies and Crohn’s disease which are 
characterized by inappropriate immune response to food antigens and intestinal bacteria 
respectively (Zeuthen et al., 2005; Vanderpool et al., 2008).   
 
               The Hygiene hypothesis suggests that if there is an altered exposure to bacteria 
during establishment of the intestinal microbiota during infancy there is development of 
an altered immune response. In a closely related concept “Old friends” are harmless 
microorganisms that are present throughout mammalian evolution. Frequent contact with 
“old friends” is hypothesized to lessen incidence of allergies (Neish, 2008). Probiotics 
may act as “old friends” through their effects on the immune system.  
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               Recent evidence suggests that probiotics of the Lactobacillus group regulate DC 
expression and cytokine production. DCs are the chief stimulators of naive T- helper cells 
and are involved in the maintenance of the delicate balance between Th1and Th2 cells. 
The development of Th1 and Th2 response is influenced by DC production of cytokines 
or chemokines. It has been reported that probiotic stimulation of DCs induced production 
of cytokines IL-10, IL-12 and TGF-β, resulting in generation of Treg cells and IgA 
producing B cells (Zeuthen et al., 2006; Neish, 2009; Walker, 2008). IL-10 is also 
produced by Treg, and suppresses IL-12 activity, preventing an inflammatory cascade of 
Th1 cytokines and cellular migration. IL-10 also prevents the activation of antigen 
presenting cells, inhibits DC maturation, T-cell proliferation, and induces a state of  
antigen-specific tolerance and Treg cell induction (Drakes, et al., 2003). Different species 
of Lactobacilli vary in their ability to induce cytokine production by DCs. Cytokine 
production patterns by DC also depend upon the concentration of the Lactobacilli species 
used. For example treatment with low concentrations of Lactobacilli casei induced the 
production of higher levels of IL-6, IL-12 and TNF-α but no IL-10 production by DC. 
Lactobacilli reuteri on the other hand down- regulated IL-12 and TNF-α production but 
induced the production of IL-10, suggesting that L. reuteri would have anti-inflammatory 
effects (Christensen et al., 2002). 
 
                       Potential health benefits of probiotics                  
               Probiotic is a term derived from the Greek word meaning “supporting or               
favouring life” and has been defined by World Health Organization (WHO) as live 
microorganisms which when administered in adequate amounts confer a health benefit on 
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the host.” (Guarner & Schaafsma, 1998). Probiotics have been studied intensely in recent 
years as they may play an important role in influencing both humoral and cell-mediated 
immunity. The commonly used probiotics are Lactobacillus, Bifidobacterium and 
Saccharomyces boulardii in food. Species of lactic acid bacteria (LAB) that are chiefly 
associated with probiotic activity include Lactobacillus acidophilus, Lactobacillus casei, 
Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus 
plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, 
Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium longum (Sanders, 1999).   
 
               The immunomodulatory effects associated with probiotics include strengthening 
of non-specific defence against infection and tumours, adjuvant effects in antigen specific 
immune responses and increase in secretory IgA production (Sanders, 2010). Most 
probiotics are Gram positive lactic acid bacteria and their cell walls are               
composed of a thick peptidoglycan layer interspersed with teichoic acids and              
polysaccharide. Exceptions include the E. coli Nissle strain, which are Gram negative              
bacteria, and Saccharomyces boulardii, a yeast. Upon entering the intestine, probiotics               
interact with intestinal epithelial cells (IECs) and DCs. Probiotics encounter DCs in the              
intestinal tract in two ways: Lamina propria DCs continuously sample the environment               
by passing their dendrites between IECs, and secondly, DC can interact with the bacteria 
which have reached the GALT through M cells. DCs recognize probiotics by the MAMPs 
(microorganism associated molecular pattern) found on the bacterial cell surface which 
interact with PRRs (pathogen recognition receptors), including TLRs expressed on DCs. 
In the case of certain Lactobacillus species, TLR2 is engaged (Lebeer et al., 2010; Hart et 
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al., 2004). The various MAMPs found on probiotics include flagella, fimbriae (both in 
case of E.coli Nissle 1971 and Lactobacillus rhamnosus GG), secreted proteins 
(Lactobacillus rhamnosus GG p40 and p75 and Lactobacillus johnsonii  EFTu and 
GroEL), glycan ligands (Lactobacillus acidophilus SlpA), capsular polysaccharide 
(Lactobacillus casei Shirota), Lipoteichoic acid (Lactobacillus plantarum), 
Lipopolysaccharide, lipid A (E.coli Nissle 1917 hexa acyl lipid A) and peptidoglycan 
(Lactobacillus plantarum DAP-PG) (Lebeer et al., 2010). This diverse array of bacterial 
components serving as MAMPs suggest that there are multiple ways in which probiotics 
can interact with DCs and influence the immune response.  
 
               Probiotics are also reported to aid in physiological functions such as lactose 
digestion and prevention of colonization by pathogenic bacteria by varied mechanisms. 
Some of the mechanisms include secreting bacteriocins, adhesins, lactic acid, QS 
(Quorum Sensing) signals, short chain fatty acids (butyric acid, acetic acid and propionic 
acid) and decrease pH. They induce increased mucin production in the intestine thereby 
interfering with pathogen attachment to intestinal epithelial cells. They also enhance tight 
junction functioning and prevent apoptosis (Lebeer et al., 2010). It has also been 
suggested that probiotics may exert anti-colon cancer effects by binding to mutagens or 
by de-activating carcinogens, through inhibition of carcinogen producing enzymes (beta-
glucuronidase and nitroreductase) produced by colonic microbes (Sanders, 1999). Certain 
probiotics produce colonization resistance inhibitors such as hydrogen peroxide and 
biosurfactants thereby preventing colonization by urogenital pathogens. Probiotics have 
also been reported to be involved in reducing blood lipids by assimilation of  cholesterol 
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and increased excretion of bile salts due to deconjugation mediated by a  hydrolase 
enzyme. Certain strains may are also be involved in anti-hypertensive effect mediated by 
the enzyme peptidases which act on milk proteins, yielding tripeptides which in turn 
inhibit the angiotensin 1 convertingenzyme (ACE). Studies have demonstrated that 
Lactobacillus helveticus is capable of releasing anti-hypertensive peptides from the milk 
protein casein such as ACE inhibitory tripeptides Val-Pro-Pro (VPP) and Ile-Pro-Pro 
(IPP) (Narva et al., 2004). Furthermore the cell wall components of certain probiotics 
have been reported to inhibit activity of the angiotensin converting enzyme (ACE), 
suggesting multiple mechanisms for ACE inhibition by probiotics in foods (Lye et al., 
2009). Probiotics may also influence effects of dietary components such as soy. Studies 
have shown that probiotic bacteria can hydrolyze isoflavone glucosides into bioactive 
aglycone form which are absorbed faster and in greater amounts than in natural 
glucosides in soy milk (Lye et al., 2009). Phytoestrogens are isoflavones which are 
structurally similar to estrogens and can bind to estrogen receptors they are sometimes 
used by women for hormone replacement (Sanders, 1999).  
                     
                     Differentiation of KG-1 cells into DLCs 
               KG-1 cells can be differentiated into DLCs using phorbol myristate acetate 
(PMA) or a combination of PMA + Ionomycin or PMA + TNF-α (St.Louis et al., 1999; 
Teobald et al., 2008; Berges et al., 2005). Other agents that can be used to induce 
differentiation are GM-CSF (Granulocyte macrophage colony stimulating factor) and 
TNF-α. KG-1 cells grow in Iscove’s medium and appear as round non-adherent cells.  
After stimulation with PMA they appear as large, loosely adherent cells with irregular 
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shapes, prominent dendritic processes and hair-like cytoplasmic projections. This 
morphological characteristic is very much similar to in vivo DC and helps in their 
identification. Differentiation can be further confirmed by assessing expression of DC- 
specific cell surface molecules (St. Louis et al., 1999; Della Bella et al., 2008 ). 
                             
 Mechanism of action of the differentiation agents 
               KG-1 cells can be differentiated into DLCs by the combination of PMA and 
Ionomycin (St. Louis et al., 1999; Ackerman and Cresswell, 2008; Teobald et al., 2008). 
PMA acts as an analogue of diacyl glycerol and activates the enzyme Protein Kinase C. 
This in turn regulates different signal transduction pathways and other cellular metabolic 
activities (Goel et al., 2007). Protein Kinase C activation causes morphological changes 
in KG-1 cells by inducing surface molecule expression and results in allostimulatory 
capacity for T-cells (St.Louis et al., 1999; Hulette et al., 2001; Berges et al, 2005). PMA 
stimulation of KG-1 cells involves activation of the NF-κB transcription family through 
up regulation of Re1B. Nuclear localization of Re1B results in increased antigen 
presentation cell activity in both KG-1 cells and human DCs thus implying that PMA 
adopts a similar pathway in both of these cells (St.Louis et al., 1999; Berges et al., 2005). 
Ionomycin is a calcium ionophore, and a polyether antibiotic produced by Streptomyces 
congloblastus ATCC 31005. Ionomycin is involved in the Ca
++
/calmodulin signalling 
pathway and also in induction of hydrolysis of phosphoinositides, and can act in synergy 




               Retinoic acid or vitamin A is essential for normal immune function and is               
involved in both innate and adaptive immunity. It is required to maintain balance of                
Th 1 and Th2 responses (Massacand et al.,2008). Without vitamin A the responses are               
skewed towards the Th1 response and antigen presenting cells have been shown to be               
the target of retinoic acid in the restoration of Th2 response (Hengesbach and Hoag,                
2004). Retinoic acid receptors (RARs) are the main targets for regulating               
myelopoiesis and are required for granulocyte development. Retinoic acid binds to               
RARs present on DNA which in turn bind to Retinoid X Receptor elements (RXRE) 
found in  promoter regions, leading to either induction or repression of transcription of  
genes responsible for differentiation of various immune cells (Coombes and Powrie,  
2008; Duester, 2008). When treated with retinyl acetate and 13-cis retinoic acid, mice  
show enlargement of lymphoid tissues due to an increase in numbers of macrophages  
and DCs. Studies have indicated that retinoic acid also promotes mDC differentiation and 
their migration to the small intestine (Hengesbach and Hoag, 2004).           
 
            Lactobacillus species as a KG-1 differentiation agent 
               Although Lactobacillus strains were never tested for their differentiation 
capacity on KG-1s, it is known that they possess immunomodulatory and 
immunostimulatory capacity based on work done using peripheral blood DCs (Hart et al., 
2003; Christensen et al., 2002). It was noted that the bacterial capacity to stimulate 
production of IL-10, IL-12, TNF-α and the amount of cell surface markers by human 
monocyte-derived DC not only varied among the different bacterial genera but also 
varied among the various species of Lactobacillus tested (Zeuthen et al., 2006). It should 
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also be noted that there are relatively few studies addressing effects of lactobacilli on DC, 
in spite of the increasing evidence for the impact of the gut microbiota on intestinal DC. 
The KG-1 model provides a potential system to examine effects of lactobacilli, and by 

















                      OBJECTIVES AND STUDY DESIGN 
In humans the DC population composes only 0.1% of all leukocytes thus making their 
isolation and ex vivo manipulation difficult. Since many studies of DCs require large 
numbers of readily available DCs, a cell line model using KG-1 was selected. The overall 
objective of this study was to examine the utility of an in vitro Dendritic cell (DC) system 
derived from the KG-1 cell line and to utilize this model for testing effects of selected 
lactic acid bacteria on dendritic cells. 
 
Specific objectives were as follows: 
1. Determine the optimal stimuli and conditions necessary to differentiate KG-1 
 
 cells into DLCs using various combinations of differentiation agents 
 
 
2. To determine the cell surface markers expressed by KG-1 DLCs in comparison  
 
with the cell surface markers expressed by undifferentiated KG-1’s. 
 
 
3. Determine effects of selected probiotics ( Lactobacillus rhamnosus R0011 and  
 
              Lactobacillus helveticus R0052) on KG-1 differentiation to the DC phenotype. 
 
4. Determine and measure the types of cytokines produced by undifferentiated KG- 
 
1s and KG-1 DLCs to further determine the DC lineage. 
 
5. Determine and measure the types of cytokines produced by DLCs obtained by  
  PMA + Ionomycin differentiation after TLR-agonist stimulation, using TLR 
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agonists best suited for mDC and pDC activation (Poly (I:C) (TLR3 agonist), 
Lipopolysaccharide (TLR4 agonist), Flagellin (TLR5 agonist), Imiquimod 
(TLR7 agonist) and unmethylated  CpG DNA (TLR9 agonist). 
 
6. To determine the effects of probiotics on KG-1 DLC DC responses to TLR-
agonists by measuring effects on cytokine production.                                     
 



















                            MATERIALS AND METHODS 
Cell culturing 
              KG-1 cells obtained from the American Type Culture Collection (ATCC) were 
maintained in Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen Inc.) 
supplemented with 20% Fetal Bovine Serum (FBS, Sigma-Aldrich Canada), and 0.05 
mg/ml Gentamicin. Cells were grown in 75 cm² tissue culture flasks (Cellstar,              
Greiner Bio-one Mississauga, Ontario). Cultures were maintained in a humidified 
incubator at 37°C in 5% CO₂ (Thermo Corporation, Toronto). Sub-culturing of the cells 
was performed every 2-3 days.  
 
Preparation of Lactobacillus strains 
              Lactobacillus rhamnosus (strain R0011) and Lactobacillus helveticus (strain 
R0052) were obtained from the Institut Rosell (Lallemand Inc; Montreal, Quebec) as 
industrially packed lyophilized cultures, at defined CFU/g. Bacteria were reconstituted by 
resuspending  an aliquot of lyophilate in 20 ml of Phosphate buffer (PBS) and 
centrifuging at 3000 xg for 20 minutes to remove extraneous materials. After 
centrifugation the supernatant was removed carefully and the pellet resuspended in PBS 
and centrifuged again two times adopting the same procedure. Finally the pellet obtained 
was suspended in 5ml PBS and the number of colony forming units/ml determined by 
serial dilution and plating on de Man, Rogosa and Sharpe (MRS) agar. The 





Differentiation of KG-1s to Dendritic Like Cells (DLCs) in vitro  
              Several differentiation agents and their combinations were used to induce KG-1 
cells to differentiate into DLCs, including Phorbol myristate acetate (PMA), Ionomycin, 
Tumour Necrosis Factor α (TNF-α), all trans Retinoic Acid (atRA). KG-1cells were 
cultured with differentiation agents at an initial concentration of 5 x 10⁴cells/ml 
(determined using Guava Viacount) unless otherwise specified. All tests of differentiation 
agents were compared with controls which contained un-stimulated KG-1s cultured under 
the same conditions and concentration, and all tests were performed in 6 well tissue 
culture plates (BD Falcon). To determine the efficacy of PMA as a differentiation agent, 
PMA (Sigma-Aldrich, Catalogue #1585) was tested for effects on KG-1 differentiation 
over a range of concentrations (10 ng/ml, 15 ng/ml, 20 ng/ml, 30 ng/ml PMA) over a 
period of 7 days. After incubation, KG-1 cells were observed under an inverted light 
microscope for production of “neurite” or “dendritic” processes. 
 
             The differentiated cells were identified as DLCs using direct 
immunofluorescence and flow cytometry (using a Guava Personal Cell Analysis or 
Guava PCA) to measure cell surface marker expression. In addition, KG-1 cells (at a 
concentration of 5 x10⁴ cells/ml) were stimulated with the combination of PMA at 10 
ng/ml + Ionomycin  at 100 ng/ml (Sigma-Aldrich, Canada) for 3 or 5 days. Additional 
testing of PMA and Ionomycin at these concentrations with KG-1 cells at 8 x10⁴ cells/ml 
for 5 days was also carried out, again observing morphological changes and cell surface 
marker expression. The effect of PMA and Ionomycin was also tested at a higher 
concentration (20 ng/ml PMA+ 200 ng/ml Ionomycin) for 7 days. The combination of 10 
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ng/ml PMA + 10 ng/ml TNF-α (Sigma-Aldrich) was also tested, observing KG-1 
differentiation over 7 days. all trans Retinoic acid (atRA) (Sigma Aldrich; Catalogue 
#R2625) was tested at a concentration of 1µM (Darmanin et al., 2007), observing effects 
on KG-1 differentiation over 5 days. All preparation of atRA was performed in subdued 
light as atRA is highly light sensitive. A stock solution of atRA at 0.001M stores for two 
weeks without deterioration in absolute ethanol at -70ºC. Stock solutions in absolute 
ethanol were dispensed in dark colour vials (suitable for storing light sensitive materials), 
flushed with nitrogen gas for 10 minutes and stored at -70C. Samples for assay were 
withdrawn using a needle and syringe. 
                
               In addition, Lactobacillus rhamnosus R0011 and Lactobacillus helveticus 
R0052 (at concentrations of 2 x 10⁸ CFU/ml and 1 x10⁸ CFU/ml) were also tested for 
their KG-1 differentiation capacity. Lactobacillus rhamnosus R0011 at a concentration of 
1 x10⁸ CFU/ml was selected as the optimal strain and concentration, based on initial 
testing of effects on KG-1 viability.  
 
Cell viability measurement 
               Cell viability was determined using the Guava Viacount assay, performed using 
a Millipore® Guava Personal Cell Analysis (PCA; Millipore, Billerica, MA, catalogue 
#0500-1090). The Viacount Reagent (Millipore, Catalogue #4000-0041) contains two 
proprietary DNA binding dyes, and differentially stains viable and non-viable cells based 
on their differential permability to a membrane-impermeant DNA binding dye. (Only 
non-viable cells are permeable to this dye.)  A membrane-permeant dye in the Viacount 
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Reagent mixture stains all nucleated cells, whether alive or dead. The Guava PCA counts 
the stained nucleated events and then uses the forward light scatter (FSC) properties to 
distinguish free nuclei and cellular debris from cells to obtain an accurate viable count. 
Cytosoft™ Software was used for data acquisition and analysis by enabling the 
EasyFit™ feature. The EasyFit performs analysis in three dimensions and allows better 
discrimination of live cells, dead cells and debris when they overlap with each other. 
Cells were diluted 1/20 in Viacount Reagent and incubated for 5 minutes before 
analyzing the sample. The Guava PCA was calibrated before reading samples using the 
Guava Check software and Guava Check kit (Millipore, Catalogue # 4500-0020). Data 
was collected (1000-2000 events per sample) using the Guava ViaCount software and 
saved to an FCS 2.0 file and an Excel spread sheet file.  
 
Immunofluorescence and flow cytometric analysis 
               Flow cytometry uses the hydrodynamic principle of passing fluorochrome-              
labelled cells through a laser beam to excite the fluorochrome, resulting in emission of 
photons. The scattered photons are collected by optical detectors and converted into 
electrical pulses. The most common optical detector is a photo multiplier tube (PMT) 
which collects electrical impulses and amplifies them. The amplified signals are then               
processed by an Analog to Digital Converter (ADC) into graphical signals that appear as 
histograms. One-parameter histograms were generated in this research with the x- axis 





               Cell surface marker analysis was initially conducted on two kinds of samples. 
The first sample was drawn from the top of the well and was labelled as “non adherent” 
cells and the second type of sample was withdrawn from the bottom part of the well and 
labelled as “adherent” cells. The cells at the bottom of the well were harvested by 
detaching them with a solution of 1mM EDTA (Sigma Aldrich) + PBS for 10 minutes at 
37°C in 5% CO₂. The detached cells were spun at 300xg for 10 minutes and the pellet 
was suspended in 1ml of cell staining buffer (2% FBS in PBS). The cells were counted 
by Guava Viacount and were later stained with PE-labelled anti-human antibodies or 
their isotype controls by incubating them in the dark for 30 minutes on ice. After 
incubation, the cells were spun at 300xg for 5 minutes and washed twice with 1ml of cell 
staining buffer. The final pellet was re-suspended in 0.5 ml cell staining buffer and placed 
on ice in the dark until analysis (3 to 5 minutes). The processed samples were analyzed 
by flow cytometry using the “Guava Express” program. 
 
               Monoclonal antibodies used for direct immunofluorescence were PE-labelled 
anti-Human CD83 (BioLegend, SanDiego, CA, Catalogue #305307), PE -labelled anti-
Human CD11c (BioLegend, Catalogue #301605), PE-labelled anti-Human CD123 
(BioLegend, Catalogue #306005), PE-labelled anti-Human CD86 (BioLegend, Catalogue 
#305406), PE labelled anti-Human HLA-DR (BioLegend, Catalogue #307605) or PE-
labelled anti-Human CD80 (BioLegend, Catalogue #305307) and PE-labelled anti-
Human DC-SIGN (BioLegend, Catalogue #343003). PE-labelled mouse IgG1, κ 
(BioLegend, Catalogue #400114), PE-labelled mouse IgG2b, κ (BioLegend, Catalogue 
#400314) and PE-labelled mouse IgG2a, κ (BioLegend, Catalogue #400211) were used 
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as isotype control antibodies, matched to the appropriate test antibodies. The Guava 
Express Assay identifies specific cell populations based on their expression of cell 
surface molecules. The software uses two fluorescence parameters in combination with 
forward angle light scatter (FSC) to identify cells with specific phenotypic markers. 
Fluorophore-conjugated antibodies are able to bind specific surface molecules on the 
cells, labelling them, and the Guava PCA can detect the intensity of fluorescence signals 
on individual cells as well as determining the number of cells labelled. The fluorophore 
used throughout for direct immunofluorescence was phycoerythrin (PE). Data including 
mean fluorescence intensity (MFI), percent coefficient of variance (CV%), and the 
resulting histograms generated were exported to FCS 3.0 files and saved in Excel 
spreadsheet files. Detailed analysis including use of the Overton subtraction for 
determination of percentage of cells staining positive and the MFI of selected cell 














Table 2: Anti-Human antibodies required for identifying dendritic cells 






Markers Role  Antibodies 




























Mouse IgG2b, к 






Mouse IgG1, к 
























Mouse IgG2b, κ 
HLA-DR (MHC 
class II) 
Markers of APCs; 




class II MHC) 
 
 
Mouse IgG2a, к 
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Determination of cytokine production profiles and kinetics  
                KG-1 DLCs obtained after differentiating KG-1 cells with the combination of 
PMA (10 ng/ml) and Ionomycin (100 ng/ml) were collected from the bottom of 6 well 
culture plates after treatment with 1mM EDTA+ PBS  solution for 10 minutes at 37°C in 
5% CO₂. The adherent cells from replicate wells were pooled, cells were washed by 
centrifugation, and viability and cell concentration measured using the Guava Viacount 
assay.  The viability of KG-1 DLCs was typically 90%. Differentiated KG-1 DLCs were 
then cultured in 96 well tissue culture plates (Cellstar, Greiner Bio-One) to determine 
cytokine production profiles.   
 
               To determine cytokine production profiles, KG-1 DLCs were tested at 
concentrations of 1 x10⁶ cells/ml and 2 x10⁶ cells/ml, using a panel of TLR agonists. LPS 
(Sigma Aldrich, Catalogue #L2654), a TLR4 agonist, was tested at 0.1 µg/ml, 1 µg/ml 
and 10 µg/ml concentrations to determine the optimal dose for cytokine induction. The 
TLR3 agonist Poly (I:C) (Sigma Aldrich, Catalogue # P1530) was tested at 
concentrations of 100 µg/ml, 50 µg/ml, 25 µg/ml and 5 µg/ml. The TLR5 agonist 
Flagellin (Invivogen) was tested at concentrations of 10 ng/ml, 1 ng/ml and 0.1 ng/ml. 
The TLR7 agonist Imiquimod (Sigma Aldrich, Catalogue #I5159) was tested at 
concentrations 10 µg/ml, 5 µg/ml and 2.5 µg/ml and the TLR9 agonist unmethylated 
CpG DNA (Imgenex Crop.) was tested at concentrations of 20 µg/ml, 10 µg/ml and 5 
µg/ml. KG-1 DLC were cultured with TLR agonists in a final volume of 200µL per well, 
in triplicates, and negative control cultures containing KG-1 DLCs (cultured without TLR 
agonists) were included in all tests. Cell culture supernatants were withdrawn after 4 
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hours and 16 hours by first centrifuging the 96 well plates and then transferring the 
supernatant to a fresh 96 well tissue culture plate. The plates were immediately frozen at -
80°C until analysis for production of cytokines IL-12, TNF-α and IL-10 and TGF-β1 by 
ELISA. The plates used for TGF-β sample collection were treated with a silicon solution 
(Sigmacote, Sigma Chemical Cot) to prevent TGF-β attachment to the plastic surface. 
The same procedures were also used to determine cytokine production profiles of KG-1 
DLCs obtained by differentiation with Lactobacillus rhamnosus R0011, and to determine 
the effects of R0011-induced differentiation on the KG-1 DLC response to TLR agonists.       
 
Cytokine measurement by Enzyme Linked Immunosorbent Assay (ELISA) 
               All buffers and reagents were prepared and used in accordance with the 
manufacturers’ protocols for  IL-12 (p70) (BioLegend Inc, San Diego, California, 
Catalogue # 430201), TNF-α (BioLegend Inc, San Diego, California, Catalogue # 
431701), IL-10 ELISA kits (Biosource International Inc, Camarillo, California, 
Catalogue # CHC1323) and TGF-β1 (R&D systems Inc, Minneapolis, USA, Catalogue # 
DY240). Polystyrene high binding, Microlon 600 ELISA plates (Greiner Bio-one, 
Catalogue # 655061) was used for all ELISA assays. Table 1 and 2 compares buffer 
compositions and protocols for each ELISA kit. A standard curve was conducted for each 
ELISA to allow accurate determination of the concentration of each cytokine in the 
samples tested. For measurement of IL-12(p70) and TNF-α, plates were coated with 
either anti-IL-12 capture antibodies or anti-TNFα capture antibodies as per 
manufacturer’s protocol and plates incubated overnight at 4ºC. A blocking step was 
carried out using 1% BSA in PBS (Assay diluent) and incubating plates for 1 hour with 
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shaking at room temperature to block non-specific binding. Biotinylated anti-IL-12 
detection antibody and the biotinylated anti-TNFα detection antibody were prepared 
according to manufacturers’s protocol. Avidin-conjugated horseradish peroxidase (HRP) 
was used at a1:1000 dilution in assay buffer, and 1.8 N H₂SO₄ was used as a stop 
solution for all ELISAs. 
 
               The IL-10 ELISA was performed using anti-human IL-10 capture antibodies at 
a concentration of 1 µg/ml in coating Buffer, and anti-human IL-10 detection antibody at              
a concentration of 0.16 µg/ml in assay buffer. HRP-conjugated streptavidin was used at a 
1/1250 dilution, and 1.8 N H₂SO₄ was used as a stop solution.  
 
               Human recombinant IL-12(p70), TNF-α, IL-10 and TGF-β1 were used as 
standards in the appropriate ELISAs and the plates were read at 450nm wavelength 
(reference wavelength of 650nm) using a plate reader (Bio-Tek Instrumentation,   
Nepean, Ontario). Data was collected with KC4 program for windows (Bio-Tek) and 
compiled using Microsoft® Excel® (Microsoft Corp., Redmond, Washington, U.S.A). 
 
Statistical Analysis   
               Data are presented as mean ± Standard Error of the Mean (where n permits) and 
analyzed using a one-way analysis of variance (ANOVA). In case of ELISAs, each               
sample was tested in triplicate in each ELISA and assigned an average value. Therefore, a 
value represented as n = 1 is equivalent to a triplicate average for any single sample. For 
flow cytometry, 1000 to 2000 events were collected for each sample tested.  
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Table 3: Composition of assay solutions for TNF-α, IL-12(p70), IL-10 and TGF-β1 
ELISA kits.   
 TNF-α IL-12(p70) IL-10 TGF-β1 
 
Solutions Mass per Litre Mass per litre Mass per litre Molar 
Coating 
Buffer 
8.4 g NaHCO3, 
3.56g Na2CO3, 
pH 9.5 
8.4 g NaHCO3, 
3.56g Na2CO3, 
pH 9.5 
8.0 g NaCl, 
1.13g Na2HPO4, 
0.2g KH2PO4 
0.2g KCl, pH to 
7.4 
137 mM NaCl, 



















FBS, pH 7.4 
8.0 g NaCl, 1.13 
g Na2HPO4, 0.2 
g KH2PO4, 0.2 g 
KCl, 5.0 g BSA, 
pH to 7.4 
137 mM NaCl, 






20, pH 7.4 
  
 



















20, pH 7.4 
137 mM NaCl, 










TMB TMB 1:1 H2O2:TMB 1:1 H2O2:TMB 
 
 











                                          RESULTS 
Effects of PMA on KG-1 differentiation 
               KG-1 cells treated with PMA were compared with controls containing             
unstimulated KG-1 cells incubated under identical condition for 7 days (Figure 1). KG-1 
cells at a concentration of 5x10⁴ cells/ml treated with 10 ng/ml PMA for 7 days showed 
poor differentiation, as indicated by production of only 0-1 cells producing “neurite-like 
processes” per randomly selected field of vision as observed by microscopy. A 
representative field of view is shown (Figure 2). Other PMA concentrations (15 ng/ml 
and 20 ng/ml) tested on KG-1s for 7 days produced only 0-2 cells differentiated per 
randomly selected field of vision (Figure 5 and 6) and PMA at 30 ng/ml did not induce 
any improvement in “neurite- like process” production.  
 
               KG-1 cells treated with PMA at 10 ng/mL for 7 days showed lower expression 
of CD83 than did control cells (CD83 MFI = 43.9; control MFI = 80.5). After stimulation 
of KG-1 with 20 ng/ml PMA, CD83 expression was also lower (MFI = 47.4) compared to 
the control (MFI = 59.19) (Figure 10). This indicated that PMA at concentrations of 10 
ng/ml and 20 ng/ml caused minimal KG-1 differentiation. Moreover, both the adherent 
and non-adherent cell populations from KG-1 cultures treated with 10 ng/ml PMA 
expressed low CD83 levels (MFI = 79.3 and 74.3 respectively). There was not much 
difference between the control MFI value and the test MFI of adherent and non-adherent 





Effects of the combination of PMA and TNF-α on KG-1 differentiation 
               KG-1s at a concentration of 5x10⁴ cells/ml treated with 10 ng/ml PMA+ 10 
ng/ml TNF-α for 7 days showed 12-14 cells per randomly selected field of vision 
producing “neurite- like” processes, but there was also extensive cell death after 7 days of 
incubation. PMA and TNFα-treated KG-1 cell cultures were compared with control 
cultures containing unstimulated KG-1 cells (Figure 10 and 9). Analysis of cell surface 
molecule expression by KG-1’s cultured at an initial concentration of  8x10⁴ cells/ml and 
differentiated by 10 ng/ml PMA+ 10 ng/ml TNF-α for 5 days showed lower MFI values 
for CD83 and CD86 expression than did non-differentiated KG-1 controls.  This change 
in CD83 and CD86 expression was observed on both adherent and non-adherent cells 
indicating that at this concentration, treatment with PMA and TNF-α led to a decrease in 
CD83 and CD86 expression (Figure 17). 
    
Effect of the combination of PMA and Ionomycin on KG-1 differentiation 
               KG-1 cells at a concentration of 5x10⁴ cells/ml treated with the combination of 
10 ng/ml PMA + 100 ng/ml Ionomycin showed small “neurite-like” processes on 3-5 
differentiated cells per randomly selected field of vision after 3 days of incubation 
(Figure 11). On extension of the incubation time for 5 days there was not much loss of 
cell viability. Again, controls containing unstimulated KG-1’s were used for comparison 
throughout (Figure 12). Initial analysis of the whole KG-1 cell population indicated that 
this combination of differentiation agents induced an increase in CD83 and CD86 
expression relative to untreated controls, and that expression of these cell surface 
molecules increased with time. PMA + Ionomycin-treated KG-1 cells had an MFI value 
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of 44.6 for CD83 expression after 3 days of incubation, which rose to 95.8 after 5 days of 
incubation. CD86 expression also increased, from an MFI of 58.9 on day 3 to an MFI of 
106.4 on day 5 (Figure 15). Further analysis comparing cell surface molecule expression 
by the adherent versus non-adherent differentiated KG-1 cells revealed little difference 
between them, as MFI values for CD83 and CD86 were similar for both groups of cells, 
whether obtained from the top portion of the well, or from the bottom after  removal with 
EDTA (Figure 16). When the KG-1 cell concentration was raised to 8x10⁴ cells/ml, there 
was an increase in CD83 expression by PMA + Ionomycin-treated KG-1 cells (MFI = 
124.9) compared to control cells (MFI = 89.9). CD11c expression was also elevated on 
treated KG-1 cells (MFI = 426.2) compared to control cell CD11c expression (MFI = 
155.2). CD123 showed a marked rise in expression while CD86 expression was 
decreased by this differentiation protocol.  DC-SIGN and HLA-DR expression did not 
vary much between differentiated and control cells (Figure 18). (One way ANOVA; p = 
0.04.) 
                 
               KG-1’s at a concentration of 5x10⁴ cells/ml treated with the combination of 20 
ng/ml PMA and 200 ng/ml Ionomycin for 7 days showed extensive cell death (by 
microscopy), therefore this differentiation protocol was not further characterized.  
 
Effects of all trans Retinoic Acid (atRA) as a KG-1 differentiation agent 
               Cell surface molecules expressed by KG-1cells 8 x10⁴ cells/ml stimulated with 
atRA showed some increase in CD83 expression (MFI = 54.5) compared to control KG1 
cells (MFI = 47.9) after 1 day of incubation (Figure 19). 3 days after atRA stimulation, 
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CD83 expression had increased to an MFI of 69.1, compared to the control cell MFI of 
67.5, indicating that effects of atRA on CD83 expression were minimal. Expression of 
CD11c showed a statistically significant rise in response to atRA treatment, increasing 
from an MFI of 132.3 on control cells to an MFI of 231.2 on atRA-treated cells (One way 
ANOVA; p < 0.0001). CD123 expression was also significantly elevated, from an MFI of 
79.7 on the control cells to an MFI of 146.5 on the atRA-treated KG-1 cells (Figure 20) 
(One way ANOVA; p < 0.0001). However, the cell yield was low and the viability of the 
atRA-treated KG-1 cells was 89.7% compared to the control sample viability of 92.7%.   
 
Effects of Lactobacillus rhamnosus R0011 on KG-1 differentiation  
               Cell surface molecule expression was measured on adherent KG-1’s after 5 days 
of treatment with L. rhamnosus R0011. CD83 expression was higher on strain R0011-
treated cells than on control KG-1 cells, showing that KG-1s had differentiated into 
DLC’s. Expression of CD123 was higher on R0011-treated cells than on control           
cells. However, expression of CD11c, CD86 and HLA-DR did not vary much on R0011-             
treated KG-1 cells relative to control cells. DC-SIGN expression was low on both              
control and R0011-treated KG-1 cells (One way ANOVA p =0.0001.) (Figure 21).  
 
Cytokine production profile of KG-1s and KG-1 DLCs 
               Undifferentiated KG-1 cells and PMA + Ionomycin-derived DLCs produced              
minimal amounts of cytokines IL-12 and TNF-α even when stimulated with TLR-              
agonists, whether measured at 6 or 24 hours after stimulation (Table 3). Although the 
standard curves for these ELISAs indicated they were performing optimally, levels of 
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these cytokines in the KG-1 media samples were often below the reliable detection limit. 
Cytokine production by KG-1 cells differentiated with Lactobacillus rhamnosus R0011 
and treated with TLR-agonists was also minimal after 4 and 16 hrs (Table 4). Stimulation 
of R0011-differentiated KG-1s with either flagellin (at 10 ng/ml) or Poly I:C at 50 µg/ml) 
(Table 5) induced IL-10 production at 4 hours, with lower levels evident at 16 hours after 
TLR agonist addition. PMA+ Ionomycin-derived KG-1 DLC’s produced almost no TNF-
α and IL-12 when stimulated with TLR-agonists. PMA + Ionomycin-derived KG-1 DLCs 
showed a decrease in IL-12 and TNF-α production after 16 hours. Preliminary results 
indicated that stimulation with flagellin induced TGF-β1 production by both PMA + 






Figure 1. Control KG-1 cells after 7 days of incubation. Results obtained by light 
microscopic examination (40X magnification) of control samples containing KG-1 cells 





Figure 2. PMA-treated KG-1 cells after 7 days of incubation. KG-1 cells were seeded at a 
concentration of 5x10⁴ cells/ml and 10 ng/ml PMA. Production of distinct “neurite- like” 
processes was evident after 7 days by light microscopy at 40X magnification. 
  
“Neurite-




Figure 3. Control KG-1 cells. KG-1 cells seeded at a concentration of 5 x10⁴ cells/ml 





Figure  4. PMA-treated KG-1 cells after 7 days of incubation. KG-1 cells were seeded at 
an initial concentration of 5 x10⁴ cells/ml with PMA at 10 ng/ml. Neurite-like extensions 






Figure 5. PMA-treated KG-1 cells seeded at a concentration of 5 x10⁴ cells/ml and 
incubated with 15 ng/ml PMA. Production of “neurite-like” processes was observed by 





Figure 6. PMA-treated KG-1 cells seeded at a concentration of 5 x 10⁴ cells/ml and 
incubated with 20 ng/ml PMA. Production of “neurite-like” processes was observed by 





Figure 7: Control KG-1 cells. KG-1 cells at an initial concentration of 5 x10⁴ cells/ml for 




   
Figure 8: PMA + TNF-α treated cells after 3 days of incubation. KG-1 cells seeded at a 
concentration of 5 x10⁴ cells/ml and treated with 10 ng/ml PMA + 10 ng/ml TNF-α 





Figure 9: Control KG-1 cells after 7 days incubation. KG-1 cells at a concentration of 5 






Figure 10: KG-1 cells treated with PMA and TNF-α after 7 days incubation. Neurite-like 
processes were observed by light microscopy under 40X magnification. KG-1 cells were 






Figure 11: KG-1 control cells seeded at an initial concentration of 5 x10⁴ cells/ml for 
comparison with PMA + Ionomycin-treated KG-1 cells. Light microscopy under 40X 





Figure 12. KG-1 cells treated with PMA + Ionomycin after 3 days incubation. KG-1 cells 
seeded at a concentration of 5 x10⁴ cells/ml and treated with 10 ng/ml PMA +10 ng/ml 
Ionomycin for 3 days. Production of “neurite- like” processes observed at 40X 





Figure 13: CD83 and CD80 expression by KG-1 cells (cultured at 5 x10⁴ cells/ml) 
stimulated with 10 ng/ml PMA or 20 ng/ml PMA after 7 days incubation, compared to 
controls incubated under identical conditions without PMA. Results are shown as Mean 
Fluorescence Intensity (MFI) and illustrate representative cell surface molecule 
expression. Cell surface marker expression was determined by Guava PCA after staining 
cells with PE-labelled  anti-human CD83 or CD80 antibodies, and were compared to 






























Figure 14: CD83 and CD86 expression on non-adherent and adherent KG-1 cells 
stimulated with PMA (10 ng/ml) for 7 days, compared to non-stimulated control KG-1 
cells. MFI is indicated above each bar for ease of comparison. Adherent cells were 
obtained from the bottom portion of the tissue culture well and the non-adherent cells 
were obtained from top portion of the culture well (n = 1). Mean MFIs are shown above 



























Figure 15: CD83 and CD86 expression by KG-1’s differentiated with PMA+ Ionomycin. 
KG-1 cells seeded at 5x10⁴ cells/ml concentration were differentiated using 10 ng/ml 
PMA+ 100 ng/ml Ionomycin, and cell surface molecule expression was measured at 3 
and 5 days by direct immunofluorescence (n = 1). MFI is indicated above each bar for 























Figure 16: CD83 and CD86 expression on adherent and non-adherent KG-1’s 
differentiated by 10 ng/ml PMA+ 100 ng/ml Ionomycin for 5 days. KG-1s were seeded at 
an initial concentration of 5x10⁴ cells/ml and treated cells were compared with control 
KG-1 cells incubated under identical conditions (n = 1). Mean MFIs are shown above 

























Figure 17: CD83 and CD86 expression on adherent and non-adherent KG-1 cells 
differentiated with PMA + TNF-α.  KG-1’s seeded at a concentration of 8x10⁴ cells/ml 
were differentiated using 10 ng/ml PMA+ 10 ng/ml TNF-α for 5 days (n = 1). Mean 



























Figure 18: Cell surface molecule expression on PMA+ Ionomycin treated KG-1 cells. 
KG-1 cells seeded at 8x10⁴ cells/ml and differentiated by 10 ng/ml PMA+ 10 ng/ml 
Ionomycin for 5 days (n = 3). MFIs of treated cells (denoted as T) are compared with the 
control MFIs (denoted as C). Mean MFIs are shown above bars for ease of comparison. 













































Figure 19: CD83 expression by KG-1s following treatment with atRA. KG-1 cells were 
cultured at an initial concentration of 8 x 10⁴ cells/ml with atRA (1µM/ml) and control 
cells were cultured at the same concentration without atRA. CD83 expression was 
measured after 1 day of incubation and is expressed as MFI, shown relative to isotype 





























Figure 20: Expression of CD83, CD11c, CD123 and CD86 by KG-1 cells treated with 
atRA. KG-1 cells were seeded at 8 x 10⁴ cells/ml and treated with atRA (1µM/ml) and 
cell surface molecule expression was measured after 3 days incubation. Control samples 
contained KG-1s at the same concentration. (n = 3). Mean MFI is shown above each bar. 
One way ANOVA; p < 0.0001. Two asterisks denote significant difference from control 


































Figure 21. Expression of CD83, CD11c, CD123, CD86, DC-SIGN, HLA-DR on KG-
1cells treated with Lactobacillus rhamnosus R0011 compared to untreated control KG-1 
cells. KG-1 cells seeded at a concentration of 5 x10⁴ cells/ml were stimulated with 
Lactobacillus rhamnosus R0011 at a concentration of 1 x10⁴ cells/ml for 5 days. Results 
are shown as mean MFI of R0011-treated (red bars) and control (blue bars) cells (n = 3). 

























Figure 22: Cell surface expression of CD83 on KG-1 control cells. The histogram shows 
the level of fluorescence for CD83 expression in red, CD11c expression in blue, CD123 
expression in green and the isotype control (IgG1) in black. The histogram was generated 
by FCS Express Version 3 software from analysis of data obtained by direct 
immunofluorescence and flow cytometry using a Guava PCA. The Overton subtraction 
values were 1.5% positive for CD83 expression, 48.4% positive for CD11c expression 
and 80.2% positive for CD123 expression relative to isotype control.  
 
Control KG-1 cells: CD 83 (Red), CD 11c (Blue),























Figure 23: Cell surface marker expression of CD83, CD11c and CD123 on KG-1 cells 
differentiated with Lactobacillus rhamnosus R0011. KG-1s at 5x10⁴ cells/ml were 
treated with R0011 at 1x10⁸ CFU/ml for 5 days. The histogram shows CD83 expression 
in red, CD11c in blue, CD123 in green and the isotype control IgG1κ in black.  Overton 
subtraction indicated 76% positive for CD83 expression, 87.4% positive for CD11c 




CD 83 (Red), CD11c (Blue) CD123 (Green) and

























Figure 24:  Cell surface marker CD86 and DC-SIGN expression on control KG-1 cells. 
The histogram shows CD86 expression in green, DC-SIGN in navy blue and Isotype 
control IgG2b, κ in black. Overton subtraction indicated 38.2% positive for CD86 
expression 0.6% positive for DC-SIGN expression. 
 
 
Control sample KG-1: CD 86, DC-SIGN (Blue) 























Figure 25: Cell surface marker CD86 and DC-SIGN expression on KG-1 cells treated 
with R0011. The histogram shows CD86 marker in green, and DC-SIGN in navy blue 
and Isotype control IgG2b, κ in black. Overton subtraction indicated 47.1% positive for 
CD86 expression and less than 1% positive for DC-SIGN expression (0.8%). 
 
 
Test sample KG1+RO011: CD 86 (Green), DC-SIGN (Blue) 























Figure 26:  Cell surface marker HLA-DR on control KG-1 cells. HLA-DR expression is 
shown in yellow and Isotype control IgG2a in black. Overton subtraction indicated 73.1% 
positive for HLA-DR expression relative to isotype control.  
 
Control sample KG-1 cells: HLA-DR (yellow ),























Figure 27: Cell surface marker HLA-DR expression by KG-1s differentiated with 
Lactobacillus rhamnosus R0011. HLA-DR in yellow and Isotype control IgG2a in black. 










Test sample KG-1+RO011: HLA-DR (yellow ) 























Figure 28: Cell surface marker expression of CD83, CD11c and CD123 on control KG-1 
cells. KG-1s at 8x10⁴ cells/ml were incubated for 5 days. The histogram shows CD83 
marker expression in red, CD11c in blue, CD123 in green and Isotype control IgG1, κ in 
black. Overton subtraction indicated 0.1% positive for CD83, 36.8% positive for CD11c 




























Figure 29: Cell surface marker expression of CD83, CD11c and CD123 on KG-1 cells 
differentiated with PMA+ Ionomycin. KG-1s at 8x10⁴ cells/ml were treated with 10 
ng/ml PMA and 10 ng/ml Ionomycin for 5 days. The histogram shows CD83 expression 
in red, CD11c in blue, CD123 in green and Isotype control IgG1, κ in black. Overton 
subtraction indicated 47.7% positive for CD83, 83.5% positive for CD11c and 72.9% 






























Figure 30: Cell surface markers (CD86 and DC-SIGN) expressed by control KG-1s. KG-
1 cells were seeded at 8x10⁴ cells/ml concentration and incubated for 5 days. CD86 in 
green, DC-SIGN in blue and the Isotype marker IgG2b, κ in black. Overton subtraction 





























   
Figure 31: Cell surface markers expressed by PMA+ Ionomycin-treated KG-1. KG-1 
cells were seeded at 8x10⁴ cells/ml concentration and incubated for 5 days. CD86 in red, 
DC-SIGN in blue and the Isotype marker IgG2b, k in black. Overton subtraction 


































Table  4.  TNF-α production after 6 hours and 24 hours by unstimulated KG-1 and PMA 
+ Ionomycin-treated KG-1 DLC      
            TNF-α in pg/ml (6 hrs)        TNF-α in pg/ml (24 hrs)_  
TLR agonist                          KG-1s            DLCs                    KG-1s             DLCs_ 
LPS (µg/ml) 
          0.1                               none
1
               none                    none                  none 
          5                                  none                 none                    none                  none 
         10                                 none                 none                    none                  none 
Flagellin (ng/ml) 
         0.1                                 none                none                    none                   none                                                   
         1.0                                 none                none                    none                   none                                                            
        10.0                                none                none                    none                   none                                                                         
Imiquimod (µg/ml) 
         2.5                                   none                none                  none                   none                                  
         5.0                                   none                none                  none                   none                                             
       10.0                                   none                none                  none                   none                                              
Poly (I:C)  µg/ml 
         5                                       none               none                  none                   none 
        25                                      none               none                  none                   none       
        100                               62.1+0.01            none                  none                   none                    
No TLR-agonists
2
               54.5+ 11.5            none             213.4+13.4             none   
None
1
 indicates no TNF-α production detected by ELISA. Control cells were cultured 
without TLR-agonists. Results are shown as a mean of 3 replicates ± S.E. (n = 3). No 
TLR-agonists
2




Table 5: TNF-α and IL-12 production by KG-1 cells differentiated with Lactobacillus 
rhamnosus R0011.  
TLR-agonists            cytokine production at 4 hrs            cytokine production at 16 hrs___ 
LPS in µg/ml                        TNF-α              IL-12                           TNF-α              IL-12 
          0.1                                none
1
               none                           none                  none        
          5                                   none                none                            none                  none                   
         10                                  none                 none                           none                  none 
 Flagellin in ng/ml 
         0.1                                  none                 none                           none                 none                                                                        
         1.0                                  none                 none                           none                 none                                                                      
       10.0                                  none                 none                           none                 none                                                                                      
 Imiquimod in µg/ml 
         2.5                                   none                 none                          none                  none                                           
         5.0                                   none                 none                          none                  none                                                     
       10.0                                   none                 none                          none                  none                                                             
 Poly (I:C) in µg/ml 
        5                                        none                none                          none                  none             
      25                                        none                none                          none                  none                     
    100                                        none                none                          none                  none                                
 KG-1s + L.r
3
  
(No TLR-agonists)                   none                none                          none                  none 
None
1
 indicates no TNF-α or IL-12. L.r
3
 indicates Lactobacillus rhamnosus R0011. 
Results are a mean of 3 replicates ± S.E. (n=3). KG-1s + L.r
3
 indicates no TLR-agonists 





Table 6: IL-10 production by KG-1 cells differentiated with Lactobacillus rhamnosus 
R0011.  
TLR-agonist                  levels (pg/ml) after 4 hrs                        levels (pg/ml) after 16 hrs 
LPS ( µg/ml)                                    
          0.1                                       297.7+ 0.6                                             86.7+ 0.02                    
          5                                                N
2
                                                    70.2 + 0.01                  
        10                                         39.9+ 0.002                                           51.6+ 0.008          
 Flagellin (ng/ml) 
         0.1                                             none
1
                                               253.0 + 0.06                                                                      
         1.0                                        198.7+ 0.04                                                 none                                                                      
       10.0                                      2192.0 + 0.35                                         143.0+ 0.04                                                                                     
 Imiquimod (µg/ml) 
         2.5                                            none                                                         none                                           
         5.0                                            none                                                         none                                                     
       10.0                                            none                                                         none                                                             
 Poly (I:C) µg/ml 
        5                                                none                                                         none             
      25                                           28.9 + 0.001                                                  none                     
    100                                          1557.8 + 0.2                                                   none                                
 KG-1s + L.r
3
                               1249.9+ 0.08                                              170.8+0.05 
None
1
 indicates no IL-10 production detected by ELISA. L.r indicates Lactobacillus 
rhamnosus R0011. N
2
 indicates a negligible amount of IL-10 was detected. Results are 
shown as the mean of 3 replicates ± S.E. (n = 3). KG-1s + L.r
3
 indicates no TLR-agonists 




Table 7. IL-12 production by PMA+ Ionomycin-differentiated DLCs after TLR-agonist 
stimulation. 
TLR-agonist                    levels ( pg/ml) at 4 hrs                            levels (pg/ml) at 16 hrs_  
LPS (µg/ml)                                    
        0.1                                   88.9+ 0.1                                                   270 + 0.17                    
          5                                     81.7+ 0.09                                               47.4 + 0.14                  
        10                                    78.1+ 0.1                                                      none        
Flagellin (ng/ml) 
         0.1                                        none
1
                                                       none 
         1.0                                        none                                                        none 
         10.0                                   54.5+ 0.07                                             353.0 + 0.1                                                                      
 Imiquimod (µg/ml) 
         2.5                                        none                                                        none                                           
         5.0                                     73.5 + 0.08                                                 none                                                     
       10.0                                     70.9 + 0.04                                                 none                                                             
 Poly (I:C) (µg/ml) 
        5                                         51 + 0.002                                                  none               
      25                                         116 + 0.1                                                    none                     
      50                                         59.8 + 0.02                                            241.2 + 0.2                                                                                                     
  KG-1s (No TLR-agonists)     138.4+ 0.006                                                                                                             
None
1
 indicates no IL-12 production detected by ELISA. Results are shown as a mean of 






Table 8: Comparison of effects of differentiation agents on KG-1 DLC cell surface 
marker expression. 
________________________________________________________________________ 
Cell surface markers            atRA                  PMA+Ionomycin                  R0011_______ 
                               % positive    MFI       % positive       MFI        % positive         MFI 
CD83                          N              69.1           47.7           128.9              76                115.4 
CD123                       64.8          231.2          72.8           604.4              81.8             778.2 
CD11c                       44.5          146.5          82.5           211.4              87.4             206.6 
CD86                         25.6          163.5          25.1           601.9              47.1             598.7 
HLA-DR                    n/a             n/a            32.3           236.7               59.5            281.5    
DC-SIGN                   n/a             n/a            21.5             41.5                0.6              41.2 
MFI indicates mean fluorescence intensity. N indicates negligible and n/a applies to those 
tests not performed. Percent positive was determined using the Overton subtraction, and 















                                                        DISCUSSION 
              DC has gained much research attention in recent years with respect to their role 
as prime mediators of innate and adaptive immunity. For example, there is currently a 
great deal of speculation as to the potential for recruiting mucosal DCs to elicit the 
desired levels of SIgA secretion in the intestine by using oral vaccines which include 
genetically modified probiotics (Takahashi, 2009). There is also currently much debate 
regarding the ability of the gut microbiota to influence DC activity and phenotype (Rook 
and Brunet, 2004). Such current questions prompted our study to develop a system to 
differentiate DCs in vitro and use this system to test effects of lactic acid bacteria. 
Differentiation studies on KG-1 cells were conducted for the first time by St. Louis et al., 
1999. Differentiation agents studied included PMA, PMA + Ionomycin, PMA + TNF-α 
and GM-CSF with IL-4 or TNF-α, with treatment periods of 3 to 7 days. After incubation 
with the differentiation agents, KG-1 cells were analyzed for cell surface marker 
expression and emphasis was placed on expression of CD83, MHC Class II and co-
stimulatory molecule CD86 and CD80 expression. In addition the presence of Re1B 
transcription factor mRNA along with DC-CK1 chemokine mRNA was analysed by RT-
PCR to confirm that the KG-1 cells had differentiated into KG-1 DLCs. The PMA + 
Ionomycin differentiation protocol was adopted in studies of KG-1s conducted by 
Ackerman and Cresswell to determine the regulation of MHC I transport (Ackerman and 
Cresswell, 2003). Both of these studies were limited to determining the expression of cell 
surface markers and no further study to elucidate the DLC phenotypes was undertaken by 
these investigators. Furthermore no analyses of cytokine production profiles produced by 
KG-1 cells were determined. More recent work by other groups (Teobald et al., 2008 and 
Berges et al., 2005) focused on determining whether the KG-1 DLCs were in a mature or 
80 
 
immature state by examining cell surface marker expression, Re1B transcription factor 
upregulation and production of proteasome subunits. Thus to date, little research has been 
done to determine the kinds of cytokines produced by KG-1 cells. 
                
          The approaches used in the current study were based chiefly on the differentiation 
protocols published by St.Louis et al (St. Louis et al., 1999) and Ackerman and Cresswell 
(Ackerman and Cresswell, 2003). KG-1 cultures were observed by light microscopy for 
the production of “neurite-like” processes, cell adherence and cell death during the 
testing of each differentiation agent. In the very early phase, cultures initiated with 5 x10⁴ 
KG-1 cells/ml and treated with 10 ng/ml PMA revealed very few cells producing 
“neurite-like” processes by light microscopy (0-1 differentiated cells per randomly 
selected field of vision). These results indicated that 10 ng/ml PMA was not potent 
enough to effectively generate DLCs and indicated the need to test higher concentrations 
of PMA (15 ng/ml, 20 ng/ml and 30 ng/ml PMA). However, these higher concentrations 
of PMA did not induce better differentiation compared to10 ng/ml PMA and therefore 
use of PMA alone as a differentiation agent was abandoned. In the second phase of the 
differentiation studies other combinations of differentiation agents together with 10ng/ml 
PMA were tested. The combinations tested were 10 ng/ml PMA + 100 ng/ml Ionomycin, 
20 ng/ml PMA +  200 ng/ml Ionomycin and 10 ng/ml PMA +  10 ng/ml TNF-α. The 
combination of 10 ng/ml PMA + 100 ng/ml Ionomycin produced small neurite-like 
extensions on KG-1 cells after 3 days (3-5 differentiated cells per randomly selected field 
of vision) and cell viability was 90% at the end of the culture period. Extension of the 
culture period to 5 days did not result in any further cell death, and this differentiation 
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protocol was selected for further study. This effect of PMA + Ionomycin is in agreement 
with the findings of Teobald et al., 2007 and Berges et al, 2005. Other combinations (10 
ng/ml PMA + 10 ng/ml TNF-α and 20 ng/ml + 200 ng/ml Ionomycin) produced extensive 
cell death and were therefore discarded as a possible model for generating DLCs.   
 
                For further analysis of the efficacy of the differentiation protocol, KG-1 cells               
were analyzed for cell surface marker expression, using markers chosen based on their               
usefulness for determining DC subset and their relevance for DC function. The cell               
surface markers analyzed were CD83, CD11c, CD123, CD86, HLA-DR and DC-SIGN.              
In the initial stages of experimentation only expression of CD83 and CD86 or CD80               
was examined. This was because CD83 is a DC-specific marker and CD86 is a co-              
stimulatory molecule, important for DC activation of T cells. Analysis for CD80              
expression was discontinued in the later assays because CD80 is usually not found on               
unstimulated APCs and also its upregulation is much slower than CD86 (Paul, 2005).              
CD83 expression appeared low on both 10 ng/ml PMA and 20 ng/ml PMA              
Differentiated KG-1s, but the entire KG-1 population in the culture wells was used to               
assay cell surface markers (Fig 13). DLCs are loosely adherent, requiring EDTA              
treatment for effective detachment from the culture plate surface. However, it was              
apparent that not all of the cells in the differentiated KG-1 cultures were adherent- rather               
a proportion remained in suspension, while others adhered to the surface of the plate. To              
determine whether these two populations represented differentiated and non-              
differentiated KG-1s, the samples were divided into adherent (bottom portion) and non-              
adherent (top portion) samples. The adherent cells were treated with 1µM EDTA to               
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slough them off the culture wells, and the two samples were analyzed separately by            
immunofluorescence and flow cytometry. Analysis of KG-1 cells differentiated with 10             
ng/ml PMA + 100 ng/ml Ionomycin at 3 and 5 days showed an increased MFI value for              
both CD83 and CD86 on day 5 compared to day 3 (Fig 15). For this reason, a 5 day              
differentiation period instead of the 3 day period suggested by St. Louis (St. Louis et al.,              
1999) was adopted.  
 
               To improve yields of adherent DLC, the initial KG-1 culture concentration was 
raised from 5 x10⁴ cells/ml to 8 x 10⁴ cells/ml. Analysis of the adherent and the non-
adherent populations of 10 ng/ml PMA + 100 ng/ml Ionomycin-differentiated KG-1 cells 
did not show conclusive results using only CD83 and CD86 as cell surface  markers. To 
gain a clearer picture of the phenotype of the differentiated KG-1 cells, a battery of cell 
surface markers was used. Expression of CD11c and CD123 (specific markers for mDC 
and  pDC respectively) was elevated on PMA + Ionomycin- differentiated KG-1 cells 
relative to expression on KG-1 cells from untreated control cultures. When compared to 
unstimulated control KG-1s, expression of CD83 was found to be slightly but 
significantly raised on the PMA + Ionomycin differentiated KG-1 cells, showing 47.6% 
CD83 positive cells with an MFI of 128.  
               
                In a quest to obtain an ideal differentiating agent, atRA, a known stimulator of 
intestinal DCs (Hengesbach, 2004) was included among a battery of stimulators. 
Although atRA-treated KG-1 cells expressed elevated CD123 levels, they had very low 
CD83 expression. Furthermore the viability of the atRA-treated cultures decreased to 
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86% compared to the control culture viability of 90%. This led to the elimination of atRA 
as a useful differentiation agent. This result is consistent with an earlier study by Douer 
and Koeffler who observed that atRA at a concentration of 1µM/ml was lethal to KG-1 
cells (Douer and Koeffler, 1981). They attributed the decreased viability of KG-1s in the 
presence of atRA to an unknown irreversible cytotoxic effect within the cell.  
                
          Probiotics have known immunomodulatory effects in the intestine (Mileti et al., 
2009) and for this reason, strains of Lactobacillus were analyzed for their DC-               
differentiation capacity using the KG-1 model. The two strains tested were               
Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052, due to their               
previously reported immunomodulatory activity (Wallace et al., 2003; Wood et al.,                
2007; Fiander et al., 2005). Cultures were initially carried out using either strain at a               
concentration of 2 x10⁸ CFU/ml co-cultured with 5 x10⁴ cells/ml of KG-1 cells for 5               
days. Lactobacillus helveticus R0052 was eliminated from further study at this point,                
as the viability of KG-1 cells cultured with this strain was decreased to nearly 50% on                
day 1 and 12.3% after day 3. Viability of KG-1 cells treated with Lactobacillus                
rhamnosus R0011 however was 90% after day 5 in the initial set of results, making               
them an ideal choice as a differentiation agent. The DLCs obtained after KG-1 co-               
culture with strain R0011 showed increased CD83 expression along with a very high               
elevated levels of CD123 expression, suggesting a pDC phenotype. However,                
expression of the mDC marker CD11c was also increased along with HLA-DR, while               
DC-SIGN expression was very low (Data not shown for reasons discussed below).                
Analysis of the effects of the same strain of Lactobacillus at 2x10⁴ cells/ml in a later 
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series of experiments revealed decreased viability on day 3 prompting the                
reduction of the concentration of Lactobacillus to 1x 10⁴ CFU/ml in subsequent co-               
cultures. Tests with Lactobacillus rhamnosus R0011 at 1 x10⁴ CFU/ml after day 5               
showed KG-1 cells with a viability of 92%. The cell surface marker expression of KG-1               
cells treated with this lower concentration of R0011 remained high, apparently                
unaffected by the reduction in the number of probiotic bacteria added. This finding is in               
agreement with observations of Drakes et al., 2003 who reported that probiotic                
Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium breve,               
Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus delbreuckii subsp.               
bulgaricus, Lactobacillus plantarum and Streptococcus salivarius subsp. thermophilus                
at 10
7 
CFU/ml induced a marked rise in cell surface marker expression on bone                
marrow-derived  DC after 5 days, a finding that lends further support to the utility of                
the KG-1 model as a useful alternative for freshly isolated human DC. The MFI for               
CD83 was 115.3 on R0011-treated KG-1 cells, while control KG-1 cells showed a MFI               
of 81.2 for CD83 expression. The Overton subtraction indicated R0011-treated KG-1               
DLC were 76% positive for CD83 expression (Figure 23). The other cell surface                
marker that significantly increased in expression was CD123 with an MFI of 778.2 on                
R0011-treated KG-1 cells compared to an MFI of 612.3 on control KG-1 cells.                 
Expression of CD11c and CD86 was not much different between 1 x10
4 
CFU/ml R0011-
treated and control KG-1 cells. Statistical analysis of cell surface marker                
expression by R0011-treated KG-1 cells indicated that expression of CD83 and CD123               




               Based on the cell surface marker expression the phenotype of DLCs obtained 
from PMA + Ionomycin differentiated KG-1s and also that of Lactobacillus rhamnosus 
R0011-differentiated KG-1s resembled that of pDCs, as CD123 expression was found to 
be higher than CD11c expression, as shown in Figures 21 and 18 (Della Bella et al., 
2008). To further confirm that the KG-1 DLCs are indeed of the pDC type, it would be 
useful to determine their ability to produce IFN-α. Detection of IFN-α can be done by 
ELISA or intracellular staining; however costs of anti-IFN antibodies were prohibitive. 
An alternative approach would be to examine IFN-α mRNA expression by RT-PCR. It 
has been reported that the KG-1 DLCs obtained by PMA + Ionomycin stimulation were 
immature DLC as they expressed low levels of CD83 on their surface (Teobald et al., 
2008; Berges et al., 2005). These authors suggested that in order to further differentiate 
the cells into fully mature DC, stimulation with GM-CSF or TNF-α or a combination of 
both was required. Based on this observation, the KG-1 DLCs derived by either PMA + 
Ionomycin treatment or by R0011 treatment appear to be representative of immature  
human DCs.  
                
               Cytokine production by DLCs was also measured to further identify the subtype 
of DC generated, and to compare responses of PMA + Ionomycin-differentiated KG-1s to 
those differentiated by R0011. Production of IL-12, IL-10 and TNF-α by KG-1 DLCs 
generated by either PMA at 10 ng/ml + Ionomycin at 100 ng/ml or by Lactobacillus 
rhamnosus R0011 and stimulated with TLR-agonists were minimal. Cytokine production 
was tested at both 4 and 16 hours after addition of TLR agonists. While it is possible that 
longer incubation periods might be needed, this does suggest that the differentiated KG-
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1s do not produce significant amounts of these cytokines. Although minimal, some IL-10 
production was detected after TLR-agonist stimulation of  R0011- differentiated KG-1s, 
and was highest at 4 hrs after LPS (0.1 µg/ml) or flagellin (10 ng/ml) addition. 
Interestingly, these results are consistent with earlier reports of induction of IL-10 
production and CD83 expression following treatment of human blood monocyte-derived 
DC with Lactobacilli (Hart et al., 2011).  
                
               IL-12 production was detected only when PMA + Ionomycin was used to 
differentiate into KG-1 DLCS, and was highest in response to stimulation with Poly I:C 
(TLR3  agonist), flagellin (TLR5 agonist), or LPS (TLR4 agonist). No IL-12 production 
was observed in response to the TLR7 agonist imiquimod. Analysis of undifferentiated 
KG-1 cells revealed minimal production of IL-12 and TNF-α in response to any of the 
TLR agonists tested. These findings are similar to the observations of Teobald et al., 
(2007), although they did not examine the response to TLR agonists. Based on only IL-12 
production, it could be deduced that the PMA + Ionomycin derived KG-1 DLCs are 
mDCs. This result is not conclusive however, as TNF-α was not detected in this group of 
KG-1 DLCs. Further analysis for IFN-α production would help in better classifying DC 
lineage. In addition, preliminary results indicate TGF-β production is induced by both 
PMA+ Ionomycin and R0011 differentiated KG-1s, a novel finding, as TGF-β production 
by KG-1 cells has not been reported elsewhere. This suggests that KG-1 DLC may 
provide a useful system to study effects of probiotics and TLR agonists on TGF-β 
production by DC, an aspect that is of interest in light of current research highlighting the 
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importance of this in DC regulatory activity, and in DC “conditioning” by the intestinal 
microbiota.   
                
               In conclusion, these results support the ability of the Lactobacilli to modulate 
surface molecule expression by KG-1 DLC and also influence their cytokine production 
ability. These results are in agreement with findings published by others examining 
effects of probiotics on human monocyte-derived DC (Hart et al., 2011; Drakes et al., 
2003). Correlations can also be drawn between KG-1 DLC activity in vitro and in vivo 
DC activity based on cytokine production. In vivo, DCs appear to be activated by the gut 
microbiota and by probiotics, often inducing a regulatory phenotype. Certain strains of 
probiotic lactic acid bacteria have been observed to enhance IL-10 production and also up 
regulate CD86 expression by DCs, thereby skewing responses away from Th1 production 
(Hart et al., 2004; Rook and Brunet, 2004; Coombes and Powrie, 2008). DCs also 
regulate adaptive T cell and B cell responses in the intestine. PP DCs produce TGF-β, 
which promotes differentiation of naive B cells to IgA- producing plasma cells. TGF-β is 
released in an inactive (latent) form, which is activated by tissue plasminogen activator 
produced by CD103
+
 DC found in the PP (Massacand et al., 2008). The results obtained 
here with respect to cell surface molecule expression, IL-10 and TGF-β production 
suggest that further study of the effects of Lactobacillus rhamnosus R0011 on KG-1 
DLCs can provide a useful model to examine effects of probiotics and gut microbes on 
human intestinal DCs- a cell population that is ordinarily extremely difficult to obtain for 




                               Suggestions for future study 
               In the future, analysis of cytokine production by differentiated KG-1 cells could 
be expanded to fully determine the effect of TLR-agonists on DLCs obtained by either 
PMA + Ionomycin or L. rhamnosus R0011 treatment. Determination of the TLR 
expression profile of differentiated KG-1 cells could also be carried out by 
immunofluorescence and RT-PCR. This would further clarify the classification of the DC 
phenotype of differentiated KG-1s to determine if they do fit into a typical mDC or pDC 
profile, or whether they may more accurately represent an intestinal DC phenotype. 
Furthermore the reasons behind the minimal production of cytokines should be assessed. 
It is possible that the time duration for cytokine production was too short, although this 
seems counter to reported times for cytokine production by DCs in response to TLR 
agonists in the literature. Analysis of IFN-α production would be valuable; however the 
cost of reagents for measurement by ELISA is prohibitive. Alternative strategies to 
determine if differentiated KG-1 DLCs do produce IFN-α could potentially be carried out 
using intracellular staining for IFN-α or by analysis of IFN-α gene expression by RT-
PCR. Another goal of the development of the KG-1 DLC model is to use them to 
examine effects of bacterial components and products of lactic acid bacteria on DC 
activity, including effects of soy and milk ferments. The KG-1 DLC model can also be 
utilized to determine effects of probiotics or fermented products in simulated 
microgravity conditions using the High Aspect Ratio Vessel (HARV). It would also be 
interesting to compare the activity of the KG-1 DLCs with DCs isolated from human 
blood although this process poses several challenges. Finally the relative ease of handling 
and maintaining KG-1 cells together with their proven differentiation to DLCs by either 
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probiotics or chemicals has the potential to provide large quantities of DCs in vitro that 
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